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Background: Serum protein acidic and rich in cysteine (SPARC) is a matricellular secreted glycoprotein that
performs several cellular functions and has been implicated in tumorigenesis in a variety of tumor types. The
chemotherapeutic agent nanoparticle albumin-encapsulated (NAB)-paclitaxel has been postulated to exploit
SPARC expression to target neoplastic cells. SPARC’s role, and potentially the role of NAB-paclitaxel, in the highly
heterogeneous class of soft-tissue sarcomas (STS) has not been investigated. Our objective was to explore the
pattern of SPARC expression and its prognostic significance in STS.
Methods: 27 tissue specimens representing various STS histologies were stained for SPARC expression by
immunohistochemistry (IHC). Staining intensity was scored blindly. Survival was determined from patients’ medical
records and analyzed using Kaplan-Meier and log-rank with respect to SPARC expression level.
Results: Elevated SPARC expression was observed in 15/27 (56%) specimens. Overall patient survival segregated
strongly based on levels of SPARC expression. Patients who expressed low-to-moderate levels of SPARC exhibited
median survival of 22.1 months, while the median survival of patients with moderate-to-high expression levels was
4.4 months (log rank; p = 0.0016).
Conclusions: SPARC expression is elevated in a significant proportion of STS specimens analyzed in this study,
but it does not appear to correlate with specific STS histologies. Given our limited sample size, we cannot draw
definitive conclusions regarding association of SPARC with STS subtype. Overall survival segregates strongly by
degree of SPARC expression, with elevated expression being adverse. If validated in a larger study, our results
suggest that trials in STS with agents potentially targeting SPARC, such as NAB-paclitaxel, should be stratified by
SPARC expression level.
Keywords: Soft-tissue sarcoma, SPARC, Nanoparticle albumin-encapsulated (NAB)-paclitaxelBackground
Soft-tissue sarcomas (STS) are a relatively rare, heteroge-
neous group of malignancies. In the United States, an esti-
mated 11,410 new cases and 4,390 deaths were anticipated
in 2013 from STS [1]. Currently, the most effective treat-
ment for localized STS is surgical resection, which is some-
times combined with adjuvant radiation therapy to improve
local control [2]. Both radiation therapy and systemic cyto-
toxic therapy are used in the treatment of primary disease
for adjuvant, neo-adjuvant, and palliative treatments.
Unresectable or metastatic disease occurs in approxi-
mately 40-60% of patients [3,4] and generally portends* Correspondence: lcranmer@uacc.arizona.edu
1The University of Arizona Cancer Center, 1515 N. Campbell Avenue, Tucson,
AZ, USA
Full list of author information is available at the end of the article
© 2014 Morgan et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.poor prognosis. The median survival of patients with
advanced disease is approximately 12 months [5,6]. Treat-
ment of advanced disease relies primarily on a limited
repertoire of systemic agents. Doxorubicin, in use since
the 1970s, remains the backbone of most sarcoma systemic
therapy, but its use is complicated by cardiotoxicity. Fur-
ther, only a minority of doxorubicin-treated patients
(estimated at 26% in a meta-analysis) demonstrates object-
ive responses to treatment [6]. Other cytotoxics frequently
employed in sarcoma therapy include ifosfamide, dacarba-
zine, gemcitabine, and taxanes [7]. With the exception of
gastrointestinal stromal tumors (GIST), targeted therapies
have played a minor role in the management of STS so
far (reviewed in [7]). Treatments available for STS, par-
ticularly when disease is unresectable or metastatic, arel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Liposarcoma 11 5 (45) 6 (55)
Leiomyosarcoma 5 3 (60) 2 (40)
Synovial sarcoma 4 2 (50) 2 (50)
Angiosarcoma 1 0 (0) 1 (100)
Rhabdomyosarcoma 1 0 (0) 1 (100)
Primitive Neuroectodermal
Tumor (PNET/Ewing’s)
5 2 (40) 3 (60)
Total 27 12 (44) 15 (56)
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all patients will require salvage therapy.
Progress in the treatment of STS has been hampered by
its heterogeneity, relative rarity, and our lack of understand-
ing of the underlying biology of STS subtypes. Sarcoma is
comprised of at least 50 distinct histological entities [4,8].
The majority of sarcoma cases exhibit multiple complex
karyotypic aberrations without consistent patterns within
each subtype [4,9]. Even in sarcoma cases that are charac-
terized by specific genetic alterations, using targeted agents
have not always led to clinical benefit despite the presence
and overexpression of the molecular target [10-13]. Thus,
fully understanding the underlying biology and characteriz-
ing the mechanisms essential for progression of each STS
subtype will likely prove critical to improve the treatment
options for this group of diseases.
Serum protein acidic and rich in cysteine (SPARC), also
known as osteonectin or basement-membrane-40 (BM-40),
is a matricellular secreted glycoprotein. Initially, SPARC
was identified as a bone-specific phospho-protein [14],
but later was identified as a serum albumin-binding glyco-
protein secreted by endothelial cells [15]. SPARC is involved
in a number of cellular functions, including modulating
cellular attachment, decreasing cellular adhesion, and
inducing proliferation [16-19]. Even though SPARC has
been implicated in tumorigenesis, the specific SPARC-
mediated mechanisms involved in cancer have not been
definitively elucidated, likely due to the diversity of SPARC
functions. SPARC expression patterns appear to correspond
with different outcomes in different cancer types. In
some tumor types (e.g., breast, melanoma, and glioblast-
oma), SPARC expression levels correlate with more
aggressive behavior, while the opposite is true in other
types (e.g., ovarian, colorectal, and pancreatic) [19,20]. Since
SPARC binds albumin, it was hypothesized that tumoral
SPARC may sequester albumin-conjugated molecules, such
as nanoparticle albumin-encapsulated (NAB)-paclitaxel
[20,21]. SPARC may then facilitate the accumulation of
NAB-paclitaxel in the tumor and potentially increase its
effectiveness. Indeed, SPARC expression has been shown
to correlate with response to NAB-paclitaxel in head
and neck cancer patients [21]. However, further investiga-
tions are necessary to determine whether NAB-paclitaxel
exploits SPARC expression to target tumor cells.
The goal of this study is to explore the pattern of




The pathology archive at the University of Arizona Medical
Center (UAMC) was queried for sarcoma tissue samples
surgically resected from patients at UAMC between
2000 and 2007. After review, 27 formalin-fixed paraffin-embedded (FFPE) tissue blocks representing a range of
sarcoma histologies were identified, as outlined in Table 1.
The specimens were selected based on their availability
in the archives and suitability for immunohistochemistry
(IHC). No information on clinical outcome was used a
priori to select cases. Clinical data was obtained thereafter,
allowing estimation of survival from date of diagnosis of
unresectable or metastatic disease to the date of either
death or last date of follow-up.
Immunohistochemistry, SPARC staining and scoring
The Tissue Acquisition and Cellular/Molecular Analysis
Shared Service (TACMASS) core facility at the University
of Arizona Cancer Center (UACC) cut and prepared
5-micron thick slides from each tissue block. IHC for
SPARC was performed using mouse monoclonal antibody
(Abnova, Taipei City, Taiwan). Human glioblastoma tissue
was used as the positive control at a dilution of 1:300.
Tissue sections were stained with Discovery XT Automated
Immunostainer (Ventana Medical Systems, Inc., Tucson,
AZ; VMSI) using VMSI-validated reagents for deparaffini-
zation, cell conditioning (antigen retrieval with a borate-
EDTA buffer), primary antibody staining, detection and
amplification using a biotinylated-streptavidin-HRP and
diaminobenzidine system and hematoxylin counterstain-
ing. Following staining, slides were dehydrated through
graded alcohols to xylene and coverslips were applied
using mounting medium.
The reviewing pathologist was blinded with respect to
any clinical information regarding the cases of interest.
Staining of SPARC was reviewed and scored using path-
ology long scores [22,23]. The pathology long score is a
semi-quantitative system that represents the percentage
of positive stained tumor cells, ranging from 1 to 100%,
that exhibit different staining intensities. The staining
intensity scale ranges from 1+ to 3+, where 1+ represents
low positivity; 2+ represents moderate positivity; and 3+
represents strong positivity. Long scores are calculated
by multiplying the intensity by the percentage. As an
example, if a specimen is scored as 1+ 80% and 2+ 20%,
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maximum long score is 300, where 100% of the tumor
specimen is exhibiting 3+ staining intensity. Patient speci-
mens were classified as low-to-moderate SPARC (depicted
as “Low SPARC”) or moderate-to-high SPARC (depicted
as “High SPARC”) based on the following criterion: if at
least 50% of the tumoral cells displayed 2+ staining (long
score is between 150 and 300), the specimen was classified
as High SPARC. Otherwise, the specimen was classified as
Low SPARC (long score < 150).
Patient survival information and statistical analysis
Patient medical records were reviewed to determine the
date of diagnosis of unresectable or metastatic disease.
The survival time was measured from date of diagnosis
of unresectable or metastatic disease to date of death
or date of last follow-up. SPARC expression levels were
correlated with patients’ survival and results were repre-
sented using Kaplan-Meier survival analysis. Differences
in survival of the two groups of patients were assessed
using the log-rank test.
Results
SPARC expression levels do not correlate with specific
STS histologies
The sarcoma tissue specimens were assessed for SPARC
expression level via IHC. Approximately half of the spec-
imens (56%; 15 out of 27) demonstrated “High SPARC”
staining, as defined above; the remainder (44%; 12 out of
27) demonstrated “Low SPARC” staining (Table 1). In
the set of specimens evaluated in this study, the level of
SPARC expression did not correlate with the underlying
STS histology of the tissue specimens; i.e. the level of
SPARC expression did not segregate with respect to STS
histology. Given the limited sample size, we cannot draw
definitive conclusions in regards to association of SPARC
and histology.
Survival of sarcoma patients strongly segregate by SPARC
expression level
To analyze the clinical significance of SPARC expression,
we assessed the impact of SPARC expression levels on
patient survival. Survival was defined as the total time
from initial diagnosis of unresectable or metastatic disease
to death or loss to follow-up. Data regarding date of diag-
nosis of unresectable or metastatic disease was determined
for 17 out of 27 patients (data regarding date of diagnosis
were unavailable for 10 patients). Only 6 of the 17 tumor
samples were collected within 1 month of diagnosis of
unresectable or metastatic disease; the remaining tumor
samples were collected more than one month before or
after the diagnosis of unresectable or metastatic disease.
Kaplan-Meier and log-rank analyses were used to compare
survival of patients (Figure 1). The median survival ofpatients in the Low SPARC group was 22.1 months (range
4-32 months), whereas the median survival of patients
in the High SPARC group was 4.4 months (range 1.4-
11.1 months). The difference in median survival between
the two groups was statistically significant (p = 0.0016).
These data are summarized in Table 2.
Discussion
We identified 27 tissue specimens representing a range
of underlying STS histologies from the pathology archives
at the University of Arizona Medical Center. We did not
attempt to identify a specific subtype to study, but rather
made a survey of STS specimens treated at our center.
As would be expected, more common STS subtypes
(liposarcoma, leiomyosarcoma, synovial sarcoma) made up
the majority (20/27, 74%) of the specimens identified, with
the remainder being less common STS subtypes. This is
consistent with our intention of undertaking a preliminary
survey of SPARC expression in STS.
About half of the specimens (56%) expressed moderate-
to-high levels of SPARC. In our sample, SPARC expression
did not clearly correlate with any specific STS histology,
but we concede that the limited sample size prevents
us from drawing definitive conclusions in this regard.
What can be said, however, is that all histologies
assessed demonstrated some specimens with elevated
SPARC expression. Elevated SPARC expression is not
peculiar to any particular subtype, but is observed in a
variety of STS subtypes.
Tissue specimens were not collected at a specific time-
point in the clinical history of each patient. The relative
timing of their collection was dictated by clinical consid-
erations. This raises the question on whether elevated
SPARC expression levels are involved in the etiology of
STS (i.e., occurs at disease baseline) or occur later as an
epiphenomenon associated with disease progression. As
noted above, eleven tumor specimens were collected more
than one month before or after diagnosis of advanced
disease. No obvious correlation of SPARC expression level
with the relative time of sample acquisition was evident
(data not shown). Since our investigation here does not
specifically address the role of SPARC in the natural
history of STS, this could be the focus of future studies.
To determine the clinical significance of SPARC ex-
pression level, we compared the survival of patients who
expressed moderate-to-high and low-to-moderate levels
of SPARC. Those with moderate-to-high levels of SPARC
expression demonstrate inferior survival as compared with
low SPARC expressors. The degree of segregation by
SPARC level is statistically significant (p = 0.0016). While
confirmation of our results in larger numbers and more
STS subtypes is necessary, our current results lead us to
hypothesize that SPARC may serve as a reliable prognostic
factor in STS.
Figure 1 Kaplan-Meier and log-rank analyses were used to compare survival of all patients segregated by SPARC expression level.
Median survival for the “Low SPARC” group is 22.1 months and “High SPARC” group is 4.4 months (Log rank: p = 0.0016).
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a therapeutic target. Agents targeting SPARC-expressing
tumors, such as NAB-paclitaxel (Abraxane, Celgene Cor-
poration), have been designed to improve the therapeutic
index of paclitaxel [24]. NAB-paclitaxel may act as a
“Trojan horse,” with the albumin encapsulation serving
to direct the paclitaxel chemotherapeutic agent to tumor
cells via binding to SPARC. While taxane monotherapy
has been shown to be active primarily in angiosarcoma
[25,26], several reports have demonstrated that taxane
combination therapy is active in STS (reviewed in [7]).
Notably, the combination of docetaxel and gemcitabine
has demonstrated superiority over gemcitabine monother-
apy in a randomized phase 2 trial in STS [27]. As such,
the combination of docetaxel and gemcitabine is widely
adopted in STS management. While NAB-paclitaxel mono-
therapy has yielded somewhat discouraging results in
STS [28], we believe that NAB-paclitaxel has not been
adequately assessed in STS yet. Should the use of NAB-
paclitaxel be further explored in STS, whether alone or
in combination therapy, our current findings suggest that
stratification by the extent of SPARC expression could
be important in determining trial outcome. The marked
differences in survival between low- and high-SPARC-
expressing STS could mask beneficial anti-neoplastic
effects, if the benefit is limited to one group. We suggest
that the group with high-SPARC expression would be







Low SPARC 12 (44) 22.1 4 – 32
High SPARC 15 (56) 4.4 1.4 – 11.1Conclusions
Our investigations highlight several important findings: i)
a significant proportion of the STS specimens investigated
exhibit elevated SPARC expression; ii) elevated SPARC did
not correlate with a specific underlying STS histology; iii)
survival of STS patients segregated strongly by SPARC
expression; and iv) SPARC levels are inversely associated
with survival of patients with STS. Given our small sample
size, however, further studies should be directed at confirm-
ing these findings in a larger number and variety of
STS subtypes, as well as exploring the temporal course
of SPARC expression in the natural history of STS.
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